Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06018766 · ClinicalTrials.gov registry record · Phase 2
LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.
A Phase 2 study of Lung Transplantation and Bronchiolitis Obliterans Syndrome, sponsored by Steven Hays, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06018766: Recruiting Phase 2 study of Lung Transplantation and Bronchiolitis Obliterans Syndrome, sponsored by Steven Hays, MD.
NCT06018766 is a Phase 2 study of Lung Transplantation and Bronchiolitis Obliterans Syndrome that is actively recruiting participants, run by Steven Hays, MD. The registered enrollment target is 30 participants, below the 334-participant average among 12 other Lung Transplantation trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06018766, a Phase 2 study of Lung Transplantation and Bronchiolitis Obliterans Syndrome, is actively recruiting participants, sponsored by Steven Hays, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn about the safety and effectiveness of LAM-001 in patients who have developed bronchiolitis obliterans syndrome (BOS), a form of chronic rejection, after lung transplantation. The main questions it aims to answer are: * Is LAM-001 safe in these patients? * Is LAM-001 effective in slowing BOS progression? Participants will: * Be randomly assigned to inhale either LAM-001 or placebo (a look-alike substance that contains no active drug) daily for 48 weeks * Attend 10 study visits (mixture of in-person and telehealth) over the 48 week period * Undergo pulmonary function testing, bronchoscopy, lab testing, and physical examination * Submit weekly home spirometry monitoring Researchers will compare participants assigned to LAM-001 versus placebo to see if LAM-001 is safely tolerated and to assess the effectiveness of LAM-001 on slowing BOS progression.
Primary Outcome
Patient's % change in FEV1 from baseline at 48 weeks or termination of treatment, whichever is earlier
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LAM-001
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-08-17 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
What NCT06018766 shows while recruiting
NCT06018766 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 334-participant average among 12 other Lung Transplantation trials with a reported enrollment target (91% lower).
The record links to 3 conditions, with Lung Transplantation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06018766 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06018766 about?
NCT06018766 is a clinical study titled "LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.". The goal of this clinical trial is to learn about the safety and effectiveness of LAM-001 in patients who have developed bronchiolitis obliterans syndrome (BOS), a form of chronic rejection, after lung transplantation. The main questions it aims to answer are: * Is LAM-001 safe in these patients? ...
What is the current status of trial NCT06018766?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2023-08-17. Estimated completion is 2026-10.
What conditions does trial NCT06018766 study?
This clinical trial studies the following conditions: Lung Transplantation, Bronchiolitis Obliterans Syndrome, Chronic Lung Allograft Dysfunction.
What interventions are being tested in trial NCT06018766?
The interventions under investigation include: Placebo (DRUG), LAM-001 (DRUG).
Who is sponsoring clinical trial NCT06018766?
This trial is sponsored by Steven Hays, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06018766 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06018766's enrollment target sits among peer trials
30 11th of 12 higher than 2 of 12 other Lung Transplantation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Transplantation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction
RECRUITING · Phase 2
-
Intravenous Immunoglobulin (IVIG) in Lung Transplantation
COMPLETED · Phase 2
-
Identifying Genetic Characteristics That Increase Risk of Primary Graft Dysfunction Following Lung Transplantation
RECRUITING
-
Trifecta-Lung cfDNA-MMDx Study
RECRUITING
-
Risk Factors That Increase the Chance of Developing Primary Graft Dysfunction After Lung Transplantation
RECRUITING
-
Transplanting Lungs From Uncontrolled Donation After Circulatory Death
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI